Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …
infected and nearly six million dead worldwide, making it the most significant pandemic …
IMM-BCP-01, a patient-derived anti–SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA. 1 and BA. 2
PA Nikitin, JM DiMuzio, JP Dowling, NB Patel… - Science …, 2022 - science.org
Monoclonal antibodies are an efficacious therapy against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). However, rapid viral mutagenesis led to escape …
syndrome coronavirus 2 (SARS-CoV-2). However, rapid viral mutagenesis led to escape …
A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants
Z Yang, Y Wang, Y Jin, Y Zhu, Y Wu, C Li… - Signal transduction and …, 2021 - nature.com
The current COVID-19 pandemic has heavily burdened the global public health system and
may keep simmering for years. The frequent emergence of immune escape variants have …
may keep simmering for years. The frequent emergence of immune escape variants have …
A broadly neutralizing monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV-2 variants of concern
HA Parray, N Narayanan, S Garg, ZA Rizvi… - PLoS …, 2022 - journals.plos.org
The emergence of new variants of SARS-CoV-2 necessitates unremitting efforts to discover
novel therapeutic monoclonal antibodies (mAbs). Here, we report an extremely potent mAb …
novel therapeutic monoclonal antibodies (mAbs). Here, we report an extremely potent mAb …
Antibodies that neutralize all current SARS-CoV-2 variants of concern by conformational locking
SUMMARY SARS-CoV-2 continues to evolve and evade most existing neutralizing
antibodies, including all clinically authorized antibodies. We have isolated and …
antibodies, including all clinically authorized antibodies. We have isolated and …
The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2
H Xiong, H Sun, S Wang, L Yuan… - Proceedings of the …, 2022 - National Acad Sciences
Antibody therapeutics for the treatment of COVID-19 have been highly successful. However,
the recent emergence of the Omicron variant has posed a challenge, as it evades detection …
the recent emergence of the Omicron variant has posed a challenge, as it evades detection …
Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization
PJ Klasse, JP Moore - Elife, 2020 - elifesciences.org
We review aspects of the antibody response to SARS-CoV-2, the causative agent of the
COVID-19 pandemic. The topics we cover are relevant to immunotherapy with plasma from …
COVID-19 pandemic. The topics we cover are relevant to immunotherapy with plasma from …
SARS-CoV-2: recent variants and clinical efficacy of antibody-based therapy
Multiple variants of SARS-CoV-2 have emerged and are now prevalent at the global level.
Currently designated variants of concern (VOCs) are B. 1.1. 7, B1. 351, P. 1, B. 1.617. 2 …
Currently designated variants of concern (VOCs) are B. 1.1. 7, B1. 351, P. 1, B. 1.617. 2 …
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
Omicron: a heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escapes approved COVID-19 therapeutic antibodies
The new SARS-CoV-2 variant of concern “Omicron” was recently spotted in South Africa and
spread quickly around the world due to its enhanced transmissibility. The variant became …
spread quickly around the world due to its enhanced transmissibility. The variant became …